Solve Therapeutics just raised a sharp $120M in an upsized, oversubscribed round, and it feels like the biotech universe just leaned in a little closer. When a clinical-stage company tackling solid tumors gets this kind of backing, it signals something stronger than momentum. It signals that the people who have already built multi-billion-dollar wins see a new path worth betting on again. Dave Johnson did it at VelosBio with a $2.75B exit and before that at Acerta Pharma with a deal that reached up to $7B, and watching him steer Solve Therapeutics with that same steady intensity feels like watching a seasoned conductor return to an orchestra that knows his cadence. Except this time he has an even bigger ensemble behind him.
CloakLink is the kind of hydrophilic linker tech that makes you wonder why the rest of the field stayed stuck in the mud so long. Too many ADCs behave like they never read the manual on circulating in human blood, falling apart early, causing toxicity and clearing out before reaching the tumor. Solve Therapeutics built a system designed to hold tight until the moment it matters, delivering the payload with the accuracy of a safecracker. SLV-154 and SLV-324 are already in Phase 1, running BOIN dose-escalation with a 27% DLT target, and the early motion says the science is behaving more like engineering than guesswork. That is a rare tone in oncology.
The roster backing this platform reads like a reunion tour of people who actually delivered. Langdon L. Miller M.D. brings approvals across oncology staples. Brian Lannutti Ph.D. and Jeff Watkins Ph.D. drive the antibody and R&D engine. Katti Jessen Ph.D. pushes the diagnostic precision that makes CloakLink more than chemistry. Jeff Schaal Ph.D. adds radiopharmaceutical talent from the Cereius acquisition. Jon Williams keeps the operational and financial structure aligned. This is a leadership group that has lived every phase from bench to acquisition, now rebuilding at full speed in San Diego and Durham.
Yosemite, founded by Reed Jobs, led the round with Dan McHugh stepping onto the board, and the presence of Abingworth, Ally Bridge Group, B Capital, Balyasny, Merck, SymBiosis, Alexandria Venture Investments, AyurMaya, DC Global Ventures, General Atlantic and Surveyor Capital turns this raise into a signal flare. These firms do not follow noise. They follow inevitability. With total funding now at $321M, Solve Therapeutics is gearing up for Phase 1b and expanding its CloakLink platform exactly when the solid tumor market is surging toward $442.79B by 2029 and ADCs climb from $12.36B to nearly $30B by 2034 with solid tumors owning 50%+ of that wave.
What makes this moment stand out is not the size of the raise but the symmetry of the strategy. Solve Therapeutics is building toward later-stage trials with a patience that looks almost old-school: no theatrics, no shortcuts, just science, scale and sustained execution. In a space full of noise, they are doing what their name promises, solving the problems that have stalled an entire class of therapies and doing it with the precision of a team that knows the stakes and still chooses clarity over chaos.
Startups Startup Funding Venture Capital Biotech Biotechnology Healthcare HealthTech Technology Innovation Tech Ecosystem Startup Ecosystem
